Sign in

    Michael Ryskin • Bank of America

    Michael Ryskin's questions to Schrodinger Inc (SDGR) leadership

    Michael Ryskin's questions to Schrodinger Inc (SDGR) leadership • Q3 2024

    Question

    Michael Ryskin of Bank of America, represented by John Kim, sought clarification on whether the delayed 2024 milestones are simply pushed to 2025 or if their achievement is now uncertain.

    Answer

    CFO Geoff Porges clarified that while no future milestone is 100% certain until experimental data is available, the company's expectation is that these milestones will be recognized in 2025 rather than 2024. He also noted that revenue from the new Novartis drug discovery collaboration is expected to be a significant contributor next year as project teams ramp up.

    Ask Fintool Equity Research AI

    Michael Ryskin's questions to Thermo Fisher Scientific Inc (TMO) leadership

    Michael Ryskin's questions to Thermo Fisher Scientific Inc (TMO) leadership • Q3 2024

    Question

    Michael Ryskin inquired about the pace of market recovery into 2025, asking if it will remain gradual or if an inflection point is expected. He also requested more detail on the pharma and biotech segment, specifically on performance differences between large pharma and smaller biotech.

    Answer

    Marc Casper, Chairman, President and CEO, explained that while specific 2025 guidance will be provided in January, he is personally excited for the year as market conditions are modestly improving and pandemic-related headwinds will lessen. He noted that in the pharma and biotech segment, biotech funding and confidence are improving, while large pharma performance shows a normal distribution. Casper emphasized that Thermo Fisher's trusted partner status is driving differentiated performance.

    Ask Fintool Equity Research AI